Stopped: Low enrollment numbers precluded completion of the study during a reasonable amount of time.
To test the ability of palifermin (a recombinant human keratinocyte growth factor) to decrease mucocutaneous injury and to promote epithelial repair in Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis Overlap, diseases in which there is extensive sloughing of the skin and mucosa, including that of the eyes, gastrointestinal tract, respiratory and genitourinary systems.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Time-to-cutaneous Re-epithelialization
Timeframe: The number of days between the start of palifermin administration and complete re-epithelialization of skin up to 14 days